



#11/145

01-30-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kisiday, *et al.*

Examiner: Naff, D.

Serial Number: 09/778,200

Art Unit: 1651

Filing Date: February 6, 2001

Attorney Docket: 0492611-0454
(MIT 8813)

Title: PEPTIDE SCAFFOLD ENCAPSULATION OF TISSUE CELLS AND
USES THEREOF

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement mailed July 1, 2002, Applicants elected
Group 1, claims 1-8.


Please charge any additional fees that may be associated with this matter to our
Deposit Account No. 03-1721.

Respectfully submitted,


Monica R. Gerber, M.D., Ph.D.
Registration Number 46,724

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Dated: December 31, 2002
3494067_1.DOC

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington, D.C. 20231
on 12-31-02



RECEIVED
JAN 07 2003
TECH CENTER 1600/2880



AA

RECEIVED

OCT 18 2001 X 18 seq-
10/15/01

TECH CENTER 1600/2900
PATENT

ATTORNEY DOCKET NO. 01997/537001

Certificate of Mailing: Date of Deposit: October 10, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Tracey Simmons

Printed name of person mailing correspondence

Tracey Simmons

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John Kisiday et al.

Art Unit: 1614

Serial No.: 09/778,200

Examiner: Not yet assigned

Filed: February 6, 2001

Customer No.: 21559

Title: PEPTIDE SCAFFOLD ENCAPSULATION OF TISSUE CELLS AND
USES THEREOF

Assistant Commissioner for Patents

Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced application, please consider the
following amendments and remarks. Please amend the application as follows.

In the Specification:

Please replace Table 1 on page 19, line 1, through page 20, line 9, with the
following table that has been re-written in "clean form".

Table 1. Representative Self-Assembling Peptides

A/	Name	Sequence (n-->c)	Modulus	Structure	SEQ ID NO
	RADA16-I	n-RADARADARADARADA-c	I	β	1
	RGDA16-I	n-RADARGDARADARGDA-c	I	r.c.	2
	RADA8-I	n-RADARADA-c	I	r.c.	3
	RAD16-II	n-RARADADARARADADA-c	II	β	4
	RAD8-II	n-RARADADA-c	II	r.c.	5
	EAKA16-I	n-AEAKAEAKAEAKAEAK-c	I	β	6
	EAKA8-I	n-AEAKAEAK-c	I	r.c.	7
	RAEA16-I	n-RAEARAEARAEARAEA-c	I	β	8
	RAEA8-I	n-RAEARAEA-c	I	r.c.	9
	KADA16-I	n-KADAKADAKADAKADA-c	I	β	10
	KADA8-I	n-KADAKADA-c	I	r.c.	11
	EAH16-II	n-AEAEAHAHAEAEAHAH-c	II	β	12
	EAH8-II	n-AEAEAHAH-c	II	r.c.	13
	EFK16-II	n-FEFEFKFKFEFEFKFK-c	II	β	14
	EFK8-II	n-FEFKFEFK-c	I	β	15
	ELK16-II	n-LELELKLKLELELKLK-c	II	β	16
	ELK8-II	n-LELELKLK-c	II	r.c.	17
	EAK16-II	n-AEAEAKAKAEAEAKAK-c	II	β	18
	EAK12	n-AEAEAEAEAKAK-c	IV/II	α/β	19
	EAK8-II	n-AEAEAKAK-c	II	r.c.	20
	KAE16-IV	n-KAKAKAKAEAEAEAEA-c	IV	β	21
	EAK16-IV	n-AEAEAEAEAKAKAKAK-c	IV	β	22
	RAD16-IV	n-RARARARADADADADA-c	IV	β	23
	DAR16-IV	n-ADADADADARARARAR-c	IV	α/β	24
	DAR16-IV*	n-DADADADARARARARA-c	IV	α/β	25
	DAR32-IV	n-(ADADADADARARARAR)-c	IV	α/β	26
	EHK16	n-HEHEHKHKHEHEHKHK-c	N/A	r.c.	27
	EHK8-I	n-HEHEHKHK-c	N/A	r.c.	28
	VE20*	n-VEVEVEVEVEVEVEVE-c	N/A	β	29
	RF20*	n-RFRFRFRFRFRFRFRF-c	N/A	β	30

“ β ” denotes beta-sheet; “ α ” denote alpha-helix; “r.c.” denotes random coil; “N/A” denotes not applicable. *Both VE20 and RF20 form a beta-sheet when they are incubated in a solution containing NaCl; however, they do not self-assemble to form macroscopic scaffolds.

Please replace Table 2 on page 21, lines 17 to 25, with the following table that has been re-written in "clean form".

A2

Table 2. Representative Peptides for Cross-Linking Study

Name	Sequence (N-->C)	SEQ ID NO
RGDY16	RGDYRYDYRYDYRGDY	31
RGDF16	RGDFRFDFRFDGRDF	32
RGDW16	RGDWRWDWRWDWRGDW	33
RADY16	RADYRYEYRYEYRADY	34
RADF16	RADFDFRFDRADF	35
RADW16	RADWRWDWRWDWRADW	36

Please replace Table 3 on page 22, lines 14 to 21, with the following table that has been re-written in "clean form".

A3

Table 3. Representative Peptides for Enzymatic Cleavage Study

Name	Sequence (N-->C)	SEQ ID NO
REEE	RGDYRYDYTFREEE-GLGSRYDYRGDY	37
KEEE	RGDYRYDYTFKEEE-GLGSRYDYRGDY	38
SELE	RGDYRYDYTASELE-GRGTRYDYRGDY	39
TAQE	RGDYRYDYAPTAQE-AGEGPRYDYRGDY	40
ISQE	RGDYRYDYPTISQE-LGQRPRYDYRGDY	41
VSQE	RGDYRYDYPTVSQE-LGQRPRYDYRGDY	42

Please replace the paragraph on page 23, line 22, through page 24, line 14, with the following paragraph that has been re-written in "clean form".

A4

A peptide with the amino acid sequence n-KLDLKLDLKLDL-c (SEQ ID NO: 43) (KLD12) was synthesized using a peptide synthesizer (Applied Biosystems) and lyophilized to a powder. A 0.5% peptide casting solution was obtained by dissolving KLD12 in a solution of 295 mM sucrose and 1 mM HEPES. Freshly isolated chondrocytes from bovine calf femoropatellar groove cartilage were re-suspended in the casting solution at a concentration of 15×10^6 cells/ml. The suspension was injected into a

Cont
A4

casting frame consisting of a 40 x 40 x 1.5 mm window supported on both faces by filter paper and a porous mesh. The casting frame was placed in a 1 X phosphate-buffered saline (PBS, which contains 150 mM NaCl and 10 mM sodium phosphate at pH 7.4) bath for 15 minutes to induce the self-assembly of the peptides into a scaffold. Preferably, the cells are incubated in the sucrose solution for less than 5 minutes, or more preferably for less than 1 minute, before PBS is added. If desired, formation of a peptide scaffold may be confirmed using phase-contrast microscopy. As a control, cells were also suspended into warm agarose (2% solution, w/w), injected into the casting frame, and placed into a cold 1 X PBS bath for 5 minutes. Both the peptide and control agarose gels were maintained in DMEM media (Gifco) plus 10 % FBS, which was changed every other day.


Kindly insert the enclosed sequence listing at the end of the application.

REMARKS

The specification has been amended to provide a unique sequence identification number for each amino acid sequence within the specification. The attached sequence listing has also been inserted into the application. No new matter is introduced by any of the amendments.

Respectfully submitted,

Date: October 10, 2001


Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\Clark-w2k1\documents\01997\01997 537001 Preliminary Amendment.wpd



21559

PATENT TRADEMARK OFFICE